Oppenheimer analyst Jay Olson sees a buying opportunity in Intercept Pharmaceuticals (NASDAQ: ICPT) following weakness in the stock amid concerns ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE